A big transformation is happening in the global generic pharmaceutical industry. As a result, stocks of most major drug companies have done badly in the past one year.

The Delhi High Court on Thursday directed former Ranbaxy Laboratories Ltd promoter Shivinder Singh to pay the money owed to Japanese pharma major Daiichi Sankyo under an arbitral award won by it in 2016.

Shivinder Singh says he decided to withdraw the case after \"repeated urging\" by his mother. He also says his decision to disassociate from his brother, and tread an independent path, stands.

Their mother Nimmi Singh has requested both her sons to engage in mediation led by family elders to settle issues, says the withdrawn application.

Ladies from the families were not supposed to ask any questions with regard to the business activities as the same were supposed to be handled by male members.

An influential 'Baba' and his family with a weakness for materialism; two young businessmen loaded with nearly Rs 10,000 crore from an asset sale; and a family confidante have together cooked a cauldron that Bollywood potboilers are made of. Their machinations wrecked a flourishing empire and vapourised nearly $3.2 billion (Rs 22,500 crore then) into thin air. Watch BusinessToday.In Editor Rajeev Dubey discuss the fall of the Singh brothers' empire.

Cars and other durables to get costlier this festive seasonWith the rupee's continuous fall against the dollar automobile and consumer goods companies are facing a tough time. This festive season will see these goods become more expensive. LG, Haier, and Godrej Appliances have hiked prices by 3-5 per cent this month. Panasonic India is expected to increase product prices by 2-3 per cent soon as reported by the Business Standard. Maruti Suzuki, the country's largest carmaker, has i...

In his petition before the National Company Law Tribunal in New Delhi, Shivinder has leveled the following charges against elder brother Malvinder and former Religare CEO Sunil Godhwani.

Shivinder Singh reveals he has split with his brother Malvinder Singh to follow his \"own path\"; holds Malvinder and Godhwani responsible for systematic undermining of the interests of their companies and their shareholders.

Nearly Rs 2,700 crore of Ranbaxy sale proceeds were transferred to firms owned by the Dhillon family and associates and senior functionaries of the RSSB sect.

How Malvinder and Shivinder Singh blew Rs 22,500 crore in less than a decade and lost control over Fortis Healthcare and Religare Enterprises.

The development has cast a shadow over the ongoing attempt to sell Fortis as these four directors were among the five who had voted in favour of Munjals-Burmans' Rs 1,800 crore bid for the healthcare firm.

Fortis Healthcare today said its shareholders have voted in favour of removal of Brian Tempest from the Board of Directors in the company's extraordinary general meeting (EGM) held on May 22.

Fortis' largest shareholder, Yes Bank, has asked the board to consider all the bids (binding as well as non-binding) despite the board recommending the Munjal-Burman offer.

The bidding war has raised the value of each Fortis share nearly 50% from the lowest offer of Rs 126 per share to Rs 185 per share. So what makes Fortis so valuable?

Drug companies are moving up the value chain, transforming into complex generic manufacturers with high end R&D facilities.

The hospital business of Fortis along with a 20 per cent stake in diagnostics chain SRL will be acquired by Manipal Hospitals and private equity investment firm TPG Capital.